Skip to main content
Figure 6 | Journal of Translational Medicine

Figure 6

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Figure 6

Vincristine does not decrease tumor growth or increase survival in nude mice bearing Tsc2-/- tumors. (a) Average tumor growth over time for vincristine and vincristine plus rapamycin treated animals. (b) Survival curve for indicated cohorts. Based on survival analysis and comparison of tumor volumes on days 23 and 65, vincristine was not effective as a single agent or in combination with rapamycin.

Back to article page